Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: to continue or not to continue

Exceptional response to trastuzumab, a monoclonal antibody against human epidermal growth factor receptor-2 (HER2/ERBB2), as manifested by prolonged absence of radiographic evidence of disease (durable complete response, DCR) is uncommon.

http://ift.tt/2ANP5Ul